Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

RING E3 ligase TRIM8 is structurally selective for UBE2N-mediated ubiquitination.

Created on 14 Oct 2026

Authors

Jane Dudley-Fraser, Diego Esposito, Katrin Rittinger

Published in

The Journal of biological chemistry. Pages 113642. Oct 13, 2026. Epub Oct 13, 2026.

Abstract

RING domains catalyse ubiquitination by stabilising a closed conformation of E2-ubiquitin (Ub) conjugates, with TRIpartite Motif (TRIM) proteins representing the largest subfamily of RING-type E3 ligases. TRIM proteins are implicated in many physiological processes and diseases. For example, TRIM8 perturbation has been variously linked to neurodevelopmental defects and several cancer types, attributed to its ubiquitination of a myriad of putative substrates. However, the molecular mechanisms behind these modifications are not yet clear. Here we show that TRIM8 has preferential functionality with the E2 enzyme UBE2N to generate K63-linked poly-ubiquitin chains. By solving the crystal structure of TRIM8 RING bound to a UBE2N-Ub conjugate, we discover that its non-canonical asparagine 'linchpin' residue belies this selectivity by failing to form key contacts required to stabilise the closed conformation of other E2 enzymes. These findings not only open the door to exploring the impact of TRIM8-mediated K63 chain formation in health and disease, but also add to a growing appreciation of the specificities of RING domain catalytic activity.

PMID:
42869147
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement